Fast excitatory transmission in the vertebrate central nervous system is mediated mainly by L-glutamate. On the basis of pharmacological, physiological and agonist binding properties, the ionotropic glutamate receptors are classified into NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) and kainate subtypes. Sequence homology between complementary DNA clones encoding non-NMDA glutamate receptor subunits reveals at least two subunit classes: the GluR1 to GluR4 class and the GluR5 class. Here we report the cloning and expression of a functional rat glutamate receptor subunit cDNA, GluR6, which has a very different pharmacology from that of the GluR1-GluR4 class. Receptors generated from the GluR1-GluR4 class have a higher apparent affinity for AMPA than for kainate. When expressed in Xenopus oocytes the homomeric GluR6 receptor is activated by kainate, quisqualate and L-glutamate but not by AMPA, and the apparent affinity for kainate is higher than for receptors from the GluR1-GluR4 class. Desensitization of the receptor was observed with continuous application of agonist. The homomeric GluR6 glutamate receptor exhibits an outwardly rectifying current-voltage relationship. In situ hybridizations reveal a pattern of GluR6 gene expression reminiscent of the binding pattern obtained with [3H]kainate.
One of the most important tasks of molecular pharmacology is the deorphanization of the large number of G-protein-coupled receptors with unidentified endogenous agonists. We recently reported the cloning and analysis of expression of a novel human family C G-protein-coupled receptor, termed hGPRC6A. To identify agonists at this orphan receptor, we faced the challenges of achieving surface expression in mammalian cell lines and establishing an appropriate functional assay. Generating a chimeric receptor construct, h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor allowed us to overcome these obstacles. Homology modeling of the hGPRC6A ATD based on the crystal structure of the metabotropic glutamate receptor subtype 1 predicted interaction with ␣-amino acids and was employed to rationally select potential ligands. Measurement of Ca 2ϩ -dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of h6A/ 5.24 and identification of L-␣-amino acids as agonists. The most active agonists were basic L-␣-amino acids, L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules. Measurement of intracellular calcium in tsA cells expressing h6A/5.24 allowed determination of EC 50 values, which confirmed the agonist preferences observed in oocytes. Cloning, cell surface expression and deorphanization of the mouse ortholog further reinforces the assignment of the agonist preferences of hGPRC6A. This study demonstrates the utility of a chimeric receptor approach in combination with molecular modeling, for elucidating agonist interaction with GPRC6A, a novel family C G-protein-coupled receptor.
The orphan glutamate-like receptor GluR␦2 is predominantly expressed in Purkinje cells of the central nervous system. The classification of GluR␦2 to the ionotropic glutamate receptor family is based on sequence similarities, because GluR␦2 does not form functional homomeric glutamate-gated ion channels in transfected cells. Studies in GluR␦2 ؊/؊ knockout mice as well as in mice with naturally occurring mutations in the GluR␦2 gene have demonstrated an essential role of GluR␦2 in cerebellar long-term depression, motor learning, motor coordination, and synaptogenesis. However, the lack of a known agonist has hampered investigations on the function of GluR␦2. In this study, the ligand-binding core of GluR␦2 (GluR␦2-S1S2) was found to bind neutral amino acids such as D-serine and glycine, as demonstrated by isothermal titration calorimetry. Direct evidence for binding of D-serine and structural rearrangements in the binding cleft of GluR␦2-S1S2 is provided by x-ray structures of GluR␦2-S1S2 in its apo form and in complex with D-serine. Functionally, D-serine and glycine were shown to inactivate spontaneous ion-channel conductance in GluR␦2 containing the lurcher mutation (EC 50 values, 182 and 507 M, respectively). These data demonstrate that the GluR␦2 ligand-binding core is capable of binding ligands and that cleft closure of the ligandbinding core can induce conformational changes that alter ion permeation.crystal structure ͉ electrophysiology ͉ isothermal titration calorimetry ͉ ligand-binding core
Membrane proteins are regulated by the lipid bilayer composition. Specific lipid–protein interactions rarely are involved, which suggests that the regulation is due to changes in some general bilayer property (or properties). The hydrophobic coupling between a membrane-spanning protein and the surrounding bilayer means that protein conformational changes may be associated with a reversible, local bilayer deformation. Lipid bilayers are elastic bodies, and the energetic cost of the bilayer deformation contributes to the total energetic cost of the protein conformational change. The energetics and kinetics of the protein conformational changes therefore will be regulated by the bilayer elasticity, which is determined by the lipid composition. This hydrophobic coupling mechanism has been studied extensively in gramicidin channels, where the channel–bilayer hydrophobic interactions link a “conformational” change (the monomer↔dimer transition) to an elastic bilayer deformation. Gramicidin channels thus are regulated by the lipid bilayer elastic properties (thickness, monolayer equilibrium curvature, and compression and bending moduli). To investigate whether this hydrophobic coupling mechanism could be a general mechanism regulating membrane protein function, we examined whether voltage-dependent skeletal-muscle sodium channels, expressed in HEK293 cells, are regulated by bilayer elasticity, as monitored using gramicidin A (gA) channels. Nonphysiological amphiphiles (β-octyl-glucoside, Genapol X-100, Triton X-100, and reduced Triton X-100) that make lipid bilayers less “stiff”, as measured using gA channels, shift the voltage dependence of sodium channel inactivation toward more hyperpolarized potentials. At low amphiphile concentration, the magnitude of the shift is linearly correlated to the change in gA channel lifetime. Cholesterol-depletion, which also reduces bilayer stiffness, causes a similar shift in sodium channel inactivation. These results provide strong support for the notion that bilayer–protein hydrophobic coupling allows the bilayer elastic properties to regulate membrane protein function.
The serotonin transporter (SERT)2 is an integral membrane protein that facilitates transport of serotonin (5-hydroxytryptamine, 5HT) across cellular membranes (1). In addition to peripheral endocrine functions, 5HT is a neurotransmitter in the brain; it is involved in control of several important physiological functions such as mood, appetite, and sexual behavior. Expressed mainly in the membrane of serotonergic neurons, SERT utilizes energetically favorable cotransport of Na ϩ to remove released 5HT from the extracellular space. Human SERT (hSERT) belongs to the solute carrier 6 (SLC6) transporter family along with highly homologous transporters for the neurotransmitters ␥-aminobutyric acid, glycine, dopamine, and norepinephrine (2-4). These transporters are important drug targets for treatment of a wide range of neurological diseases. In particular, hSERT is the molecular target for widely used drugs for treatment of depression and anxiety. Also, psychostimulants such as amphetamine and 3,4-methylenedioxy-N-methylamphetamine ("ecstasy") have hSERT as the molecular target (5-7). The selective serotonin re-uptake inhibitors (SSRIs) are a class of antidepressant and anti-anxiety drugs that function as highly selective competitive inhibitors of hSERT (8). Although SSRIs are highly important for treatment of affective disorders (6), the molecular basis for their function, including location and structure of drug binding pockets, is largely unknown and a matter of debate (9, 10). Such information is important for understanding essential aspects of drug action, ranging from selectivity profile to therapeutic efficacy. Moreover, such information is indispensable for the development of new and improved drugs targeting hSERT. The primary impediment for elucidation of the structural mechanisms of hSERT inhibition is the lack of a three-dimensional structure of the protein. Still, several residues in SERT have been identified mainly by mutagenesis studies that modulate antidepressants potency (11)(12)(13)(14)(15)(16)(17). The use of comparative molecular modeling to create structural models of ligand-hSERT interactions has previously been hampered by the low phylogenetic and functional similarity between hSERT and available template proteins (18 -21). However, high resolution crystal structures of a bacterial homolog to mammalian SLC6 transporters, LeuT (22,23), have proven excellent templates for constructing experimentally validated models of substrate and drug binding pockets in human SLC6 transporters, including the human transporters for dopamine and ␥-aminobutyric acid (24 -32).In this study, we provide an experimentally validated threedimensional model of the binding site in hSERT for the SSRI (S)-citalopram (Lexapro) using mutational analysis of hSERT paired with structure-activity data for (S)-citalopram analogs. LeuT structures are used to create homology models of hSERT, followed by docking of (S)-citalopram. Validation of binding models was performed based on the mutational dataset from 64 hSERT point mutants ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.